Stocks-ASND-Ascendis Pharma-ADR

ASND Ascendis Pharma-ADR

105.49 -0.06 (-0.06%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Performance

-1.47% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
5.91B
Day’s Range
103.17
-
106.93
52W Range
61.94
-
133.92
Volume (3M)
263.13K
Price-Earnings Ratio
-9.72
Revenue
52.96M
Top Discussions
DeepNews
$ASND (Ascendis Pharma-ADR) Ascendis Pharma (ASND) Receives a Buy from Morgan Stanley Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of $151.00. The company’s shares closed yesterday at $105.49. markets.businessinsider.com/news/stocks/ascendis-pharma-asnd-receives-a-buy-from-morgan-stanley-1032190383
MarketUpdates
Edited
$ASND (Ascendis Pharma-ADR) Q1 2023 earnings report is expected to be released
10
MAY
REPORTS
Ascendis Pharma-ADR Q1 2023 earnings report is expected to be released after market open
Notify me
ASND
ASND
Ascendis Pharma-ADR
105.49
-0.06
(-0.06%)
Trade
MarketUpdates
$ASND (Ascendis Pharma-ADR) Q1 2023 earnings report is expected to be released
MarketUpdates
$ASND (Ascendis Pharma-ADR) Q1 2023 earnings report is expected to be released
DeepNews
$ASND (Ascendis Pharma-ADR) Ascendis Pharma A/S (ASND) Stock: Analyzing the Market Value Ascendis Pharma A/S (NASDAQ: ASND)’s stock price has increased by 4.75 compared to its previous closing price of 111.36. Despite this, the company has seen a gain of 2.37% in its stock price over the last five... Show More

About Ascendis Pharma-ADR

Ascendis Pharma A/S is a biotechnology company that is dedicated to developing prodrug therapies for unmet medical needs. Founded in 2007, the company is based in Copenhagen, Denmark, and operates internationally. The company is listed on NASDAQ GS using the ticker ASND. Add this instrument to your watchlist to stay up to date on ASND share price news.
-
Employees
Hellerup, Capital Region, US
HQ
2006
Founded
Jan Møller Mikkelsen
CEO
Show More

Upcoming Earnings

10
MAY
REPORTS
Ascendis Pharma-ADR Q1 2023 earnings report is expected to be released after market open

Analyst Forecast

Consensus
Moderate Buy
Price Target
129.33

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
47
Low
Industry 
Avg. 47 
44
Environment
48
Social
48
Governance

People Also Bought